{"nctId":"NCT02333071","briefTitle":"1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder","startDateStruct":{"date":"2014-12"},"conditions":["Hypoactive Sexual Desire Disorder"],"count":723,"armGroups":[{"label":"Bremelanotide (BMT/BMT)","type":"EXPERIMENTAL","interventionNames":["Drug: Bremelanotide"]},{"label":"Placebo (PBO/BMT)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Bremelanotide","Other: Placebo"]}],"interventions":[{"name":"Bremelanotide","otherNames":["BMT","PT-141"]},{"name":"Placebo","otherNames":["PBO"]}],"eligibilityModule":{"eligibilityCriteria":"Main Inclusion Criteria:\n\n* Has met diagnostic criteria for HSDD for at least 6 months\n* Is willing and able to understand and comply with all study requirements\n* Has a normal pelvic examination at screening\n\nMain Exclusion Criteria:\n\n* Subjects should be generally healthy premenopausal females with no psychological, gynecological or urological conditions which might contribute to the sexual dysfunction, compromise study participation, or confound interpretation of the study results\n* Not currently under treatment for the sexual dysfunction and willing to forego other treatments through the course of the clinical trial","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Efficacy of a Fixed Dose of Bremelanotide as Measured by FSFI (Question Q1 and Q2), 28-day Recall.","description":"As measured by change from baseline to end-of-study in the desire domain from the FSFI (Question Q1 and Q2), 28-day recall, co-primary endpoint - FSFI desire domain.\n\nFSFI = Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. Its six subscales assess desire, arousal, lubrication, orgasm, satisfaction, and pain, by summing individual items that comprise the subscale and multiplying the sum by a factor, resulting in a score ranging from 1.2 to 6. Increasing scores on this scale represent an increase in sexual desire and is a positive outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":"1.106"},{"groupId":"OG001","value":"0.24","spread":"0.994"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.30","spread":"1.105"},{"groupId":"OG001","value":"0.77","spread":"1.138"}]}]}]},{"type":"PRIMARY","title":"Efficacy of a Fixed Dose of Bremelanotide as Measured by FSDS-DAO (Item 13)","description":"As measured by the change from baseline to End-of-Study of the Core Study in the bothered by low desire item from the FSDS-DAO (Female Sexual Distress Scale - Desire Arousal Orgasm) (item 13).: co-primary endpoint - FSDS-DAO bothered by low desire item 13.\n\nResponses range from 0 (never) to 4 (always). Decreasing scores on this scale represent an increase in sexual desire (positive outcome).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.73","spread":"1.203"},{"groupId":"OG001","value":"-0.36","spread":"1.082"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"1.21"},{"groupId":"OG001","value":"-0.9","spread":"1.10"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by the Change in Baseline to End of Study in the Number of Satisfying Sexual Events (SSEs) Associated With Study Drug Administration","description":"Patient's change, from baseline to end of study (EOS), in the number of Satisfying Sexual Events (SSEs), as measured by a response of 'Yes' to question 10 (Q10) of the Female Sexual Encounter Profile-Revised questionnaire (FSEP-R). The end point was calculated as the number of events during the last 4 weeks of treatment with Q10 = Yes minus the number of baseline events with Q10 = Yes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.44"},{"groupId":"OG001","value":"-0.1","spread":"1.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.28","spread":"1.457"},{"groupId":"OG001","value":"0.10","spread":"1.189"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in Mean Desire Score (Q3) From FSEP-R","description":"Scores range from 0 (no desire) to 3 (high desire) for an individual encounter. Change from baseline is computed as the mean of the scores from all encounters for a subject in the last 28 days minus the mean of the scores from all encounters for the subject in the last 28 days before Visit 3. Only FSEP-R data pertaining to encounters recorded within 72 hours of the encounter are included.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.09"},{"groupId":"OG001","value":"0.1","spread":"0.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.66","spread":"0.975"},{"groupId":"OG001","value":"0.38","spread":"1.107"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in Mean Satisfaction With Desire Score (Q4) From FSEP-R","description":"Patient's change, from baseline to end of study (EOS), in mean satisfaction with desire score, as measured by a response to question 4 (Q4) of the Female Sexual Encounter Profile-Revised questionnaire (FSEP-R). Responses range from 1 (Not at all satisfied) to 4 (Completely satisfied).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"1.15"},{"groupId":"OG001","value":"0.0","spread":"0.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":"1.141"},{"groupId":"OG001","value":"0.59","spread":"1.054"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the FSDS-DAO Total Score","description":"FSDS-DAO = Female Sexual Distress Scale - Desire/Arousal/Orgasm Scores range from 0 (never feel bothered) to 60 (always feel bothered).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.2","spread":"13.86"},{"groupId":"OG001","value":"-5.5","spread":"12.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.4","spread":"13.96"},{"groupId":"OG001","value":"-12.0","spread":"13.66"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Total FSFI Total Score","description":"FSFI = Female Sexual Function Index: a multidimensional self-report instrument for the assessment of female sexual function.\n\nThe FSFI total score is on a scale ranging from 2 to 36. Increasing scores on this scale represent an increase in sexual desire and is a positive outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.69","spread":"7.317"},{"groupId":"OG001","value":"0.95","spread":"5.963"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.71","spread":"8.076"},{"groupId":"OG001","value":"3.95","spread":"6.740"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Mean Level of Sexual Arousal (Q6) From the FSEP-R","description":"FSEP-R=Female Sexual Encounter Profile - Revised Scores range from 0 (not at all aroused) to 3 (highly aroused) for an individual encounter. A higher score indicates a better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.11"},{"groupId":"OG001","value":"-0.1","spread":"0.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":"1.035"},{"groupId":"OG001","value":"0.43","spread":"1.029"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Mean Satisfaction With Sexual Arousal (Q7) From the FSEP-R","description":"FSEP-R=Female Sexual Encounter Profile - Revised Scores range from 0 (not at all aroused) to 3 (highly aroused) for an individual encounter. A higher score indicates a better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"1.20"},{"groupId":"OG001","value":"-0.1","spread":"1.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":"1.170"},{"groupId":"OG001","value":"0.60","spread":"1.116"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Scored Time Spent Being Concerned by Difficulty With Sexual Arousal (Q14) From the FSDS-DAO","description":"FSDS-DAO = Female Sexual Distress Scale-Desire/Arousal/Orgasm. The outcome reported is the mean score from the 15-item self assessment. The result is on a scale ranging from 0 (\"never\") to 4 (\"always\").\n\nA higher score indicates a worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"1.24"},{"groupId":"OG001","value":"-0.4","spread":"1.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"1.23"},{"groupId":"OG001","value":"-1.0","spread":"1.12"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Arousal Domain of the FSFI (Q3 to Q6)","description":"FSFI = Female Sexual Function Index: a multidimensional self-report instrument for the assessment of female sexual function.\n\nThe score is on a scale ranging from 1.2 to 6. Increasing scores on this scale represent an increase in sexual desire and is a better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.66","spread":"1.596"},{"groupId":"OG001","value":"0.16","spread":"1.240"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.46","spread":"1.724"},{"groupId":"OG001","value":"1.08","spread":"1.581"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Total Number of SSEs","description":"Change from Baseline to EOS in the total number of satisfying sexual events SSEs that occurred within 16 hours of a study drug dosing and reported within 72 hours. A higher value indicates a better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.76"},{"groupId":"OG001","value":"-0.2","spread":"1.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":"1.676"},{"groupId":"OG001","value":"0.05","spread":"1.553"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Desire Domain of the FSFI (Q1 to Q2) Throughout the Entirety of the Double-blind Phase","description":"FSFI = Female Sexual Function Index: a multidimensional self-report instrument for the assessment of female sexual function.\n\nThe score is on a scale ranging from 1.2 to 6. Increasing scores on this scale represent an increase in sexual desire and is a positive outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.69","spread":"1.114"},{"groupId":"OG001","value":"0.23","spread":"0.933"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End of Study in the Total Score for FSDS-DAO (Item 13) Throughout the Entirety of the Double-blind Phase","description":"FSDS-DAO = Female Sexual Distress Scale - Desire/Arousal/Orgasm. The FSDS-DAO is a validated 15-item self-assessment of sexual feelings and problems. The score is on a scale ranging from 0 (\"never\") to 4 (\"always\"). A higher score indicates a worse outcome.\n\nThe score is the mean change from Baseline observed at EOS (Baseline score - EOS score) for FSDS-DAO Item 13 (feeling bothered by low sexual desire).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"1.23"},{"groupId":"OG001","value":"-0.3","spread":"1.05"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Number of SSEs Associated With Study Drug Administration Throughout the Entirety of the Double-blind Phase","description":"Mean change from Baseline to EOS in the number of satisfying sexual events SSEs that occurred within 16 hours of study drug dosing and reported within 72 hours. An increase in number reflects a positive outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.66"},{"groupId":"OG001","value":"-0.1","spread":"1.37"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":324},"commonTop":["Nausea","Flushing","Sunburn","Headache","Upper respiratory tract infection"]}}}